Rottapharm Spa

Madaus Gmbh

Massimo Maria D'Amato

Lucio C Rovati

Francesco Makovec

Antonio Giordani

Gianfranco Caselli

Ulrich Mengs

Ralf-Torsten Pohl

Peter Ferenci

Lucio Claudio Rovati

The invention relates to the use of a silibinin component for the production of a medicament that is adapted for parenteral administration for the treatment of viral hepatitis, preferably of hepatitis B or C, in particular for the reduction of the virus load. The medicament preferably contains no silidianin and/or no silichristin and/or no isosilibinin.

Silibinin component for the treatment of hepatitis

The invention relates to the combination of Andolast, a calcium-activated potassium channel opener and glucocorticoids for the treatment of patients suffering for airway diseases. Pharmaceutical compositions comprising Andoalst and glucocorticoids are also disclosed.

Combination andolast/glucocorticoids

Combination of dexloxiglumide and a proton pump inhibitor (PPI) for the treatment of patients suffering from functional dyspepsia and gastroesophageal reflux disease (GERD) is disclosed.

Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders

The invention relates to a method for relieving or ameliorating symptoms of gastroesophageal reflux disease by administering a medicament that includes the cholecystokin-2 (CCK-2) receptor antagonist itriglumide and a proton pump inhibitor (PPI).

Growing community of inventors

Monza, Italy

Massimo Maria D'Amato